Viatris Inc.
Viatris Inc. (United States) is linked to 8 FDA-registered manufacturing sites. 27 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Viatris Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/viatris-inc
Overview
Viatris Inc. was formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer. It is a global pharmaceutical company that provides a broad range of medications, including generics and specialty drugs. The company focuses on increasing patient access to affordable medications.
Core services & business areas
Registered manufacturing sites (8)
Physical sites registered with the US FDA and resolved to Viatris Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- DPT Laboratories, Ltd.San Antonio, United States · Analytical testing · Labelling
- DPT Laboratories, Ltd.San Antonio, United States · Analytical testing · Labelling
- DPT Laboratories, Ltd.San Antonio, United States · Analytical testing · Labelling
- Mylan Laboratories LimitedNashik, India · Analytical testing · LabellingSite GMP match
- Mylan Laboratories LimitedHosur, India · Analytical testing · LabellingSite GMP match
- Mylan Laboratories LimitedChhatrapati Sambhajinagar, India · Analytical testing · LabellingSite GMP match
- Mylan Laboratories LimitedDistrict - Dhar, India · Analytical testing · LabellingSite GMP match
- Mylan Technologies Inc.St. Albans, United States · Analytical testing · Labelling
FDA compliance signals
27 FDA enforcement records linked to this company.
- recall — Class III2026-10-28
Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
- recall — Class II2026-04-15
Failed Dissolution Specifications
- recall — Class II2025-01-22
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
- recall — Class II2025-01-22
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-12-18
Superpotent Drug and Subpotent Drug: potency failures obtained
- recall — Class II2024-07-24
Failed Impurities/Degradation Specifications
- recall — Class II2024-07-24
Failed Impurities/Degradation Specifications
- recall — Class III2024-05-08
Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
- recall — Class II2023-06-14
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
- recall — Class II2022-11-23
Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
- recall — Class I2022-11-16
Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
- recall — Class II2022-10-05
Presence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.
- recall — Class II2022-05-18
Failed Dissolution Specifications: low out of specification results for dissolution.
- recall — Class II2022-05-11
Failed Dissolution Specifications: low out-of-specification dissolution test results observed.
- 4832012-07-26
Complaint Handling Procedure
- 4832010-02-17
Identification of persons involved, each significant step
- 4832010-02-17
Procedures not in writing, fully followed
Is this Viatris Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.